Page last updated: 2024-09-05

sorafenib and Hyperplasia

sorafenib has been researched along with Hyperplasia in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Gong, Y; Huang, T; Huang, X; Liu, B; Wang, J; Wang, Z; Yu, Q1
Chang, CH; Chiang, WF; Feng, LY; Feng, YH; Hsiao, JR; Hsieh, JL; Huang, WT; Lin, CL; Liu, SY; Tsao, CJ; Tung, CL1
Jorda, E; Lopez, V; Marti, N; Monteagudo, C; Pinazo, I1

Other Studies

3 other study(ies) available for sorafenib and Hyperplasia

ArticleYear
Sorafenib suppresses proliferation rate of fibroblast-like synoviocytes through the arrest of cell cycle in experimental adjuvant arthritis.
    The Journal of pharmacy and pharmacology, 2021, Mar-01, Volume: 73, Issue:1

    Topics: Animals; Antirheumatic Agents; Apoptosis; Arthritis, Experimental; Arthritis, Rheumatoid; Cell Culture Techniques; Cell Cycle; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Down-Regulation; Fibroblasts; G1 Phase Cell Cycle Checkpoints; Hyperplasia; Mice; Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Rats, Sprague-Dawley; Sorafenib; Synovial Membrane; Synoviocytes

2021
Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro.
    Molecular medicine reports, 2015, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression; Head and Neck Neoplasms; Humans; Hyperplasia; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Tumor Burden

2015
Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2009, Volume: 23, Issue:8

    Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Humans; Hyperplasia; Lung Neoplasms; Male; Melanoma; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Pyridines; Skin; Skin Diseases; Skin Neoplasms; Sorafenib

2009